Amgen Inc. (ETR:AMG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 152.17B |
| Revenue (ttm) | 32.28B |
| Net Income (ttm) | 3.95B |
| Shares Out | n/a |
| EPS (ttm) | 7.30 |
| PE Ratio | 38.52 |
| Forward PE | n/a |
| Dividend | 8.53 (3.01%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 612 |
| Average Volume | 682 |
| Open | 283.35 |
| Previous Close | 283.95 |
| Day's Range | 282.10 - 284.70 |
| 52-Week Range | 243.30 - 318.05 |
| Beta | 0.52 |
| RSI | 43.83 |
| Earnings Date | Apr 25, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Is the Market Bullish or Bearish on Amgen?
Amgen's (NYSE: AMGN) short percent of float has fallen 6.64% since its last report. The company recently reported that it has 15.06 million shares sold short , which is 2.81% of all regular shares th...
Fresenius gets FDA approval for biosimilars of Amgen's bone-condition drugs
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
Biotech Stocks Slide Due to Tariff Concerns (AMGN)
Biotech Stocks Slide Due to Tariff Concerns (AMGN)
Amgen Options Trading: A Deep Dive into Market Sentiment
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ: AMGN) revealed 19 unusual trades. Delving into the details, we found 26% of traders ...
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
On Friday, March 21, 2025, the Cathie Wood -led Ark Invest made some notable trades, including significant buys and sells. Ark Invest's fund bought Iridium Communications Inc. (NASDAQ: IRDM), Beam Th...
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally. The life sciences indu...
Widely used drugs on US imports list from Europe
Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
On Thursday, Amgen Inc (NASDAQ: AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with generalized myasthenia gravis (gMG), a chronic autoimmune d...
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing * Late-Breaking Data to be Presented at AAN 2025 THOUSAND OAKS, Calif. , March 13, 2025 /PRNewswire/ -- Am...
Amgen's Options: A Look at What the Big Money is Thinking
Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ: AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled t...
Stocks beating the stock market's recent Trump slump have this in common
This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.
Amgen: Riding The MariTide Of Monthly Weight Loss
Amgen set for seven straight sessions of gains
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Phase 3 Results for Rocatinlimab in Atopic ...
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Phase 3 Results for Rocatinlimab in Atopic Dermatitis
Amgen Inc (AMGN) Announces Promising Phase 3 Results for Rocatinlimab in Atopic Dermatitis
Amgen Inc (AMGN) Announces Promising Phase 3 Results for Rocatinlimab in Atopic Dermatitis
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif. and TOKYO , March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd.
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
The Art of Valuation: Discovering Amgen Inc's Intrinsic Value
The Art of Valuation: Discovering Amgen Inc's Intrinsic Value
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
Amgen Inc. (NASDAQ: AMGN) has kicked off two crucial phase three trials for MariTide, its investigational weight loss injection. This move marks a significant step in the company’s pursuit to break i...
Amgen Inc (AMGN) Faces Shareholder Investigation Over Alleged Tax Liabilities
Amgen Inc (AMGN) Faces Shareholder Investigation Over Alleged Tax Liabilities
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc. (NASDAQ: AMGN) on be...